drugset / Trial / NCT04517188

Halodine Nasal Antiseptic in Patients With COVID-19

NCT04517188

Phase 4 Unknown 40 enrolled Halodine LLC
NaSingle-groupOpen-labelPrevention

Summary

Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use. Halodine Nasal Antiseptic is formulated for topical application PVP-I to nasal passages, and has demonstrated effectiveness against SARS-COV-2 in vitro - 99.99% inactivation within 15 seconds. This study will evaluate the ability of Halodine Nasal Antiseptic to impact SARS-CoV-2 in vivo.

Timeline

Start
2021-04-01
Primary completion
2021-07-01
Completion
2021-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Povidone-Iodine Other / unclassified 1.25 % Topical

Indications